Farringdon Capital’s ADMA Biologics ADMA Stock Holding History

Farringdon Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,411	Closed	-$167K	–	421
2025 Q3	$167K	Buy	+11,411	New	+$196K	0.04%	416

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Farringdon Capital's ADMA Position: Q4 2025 in Review

Farringdon Capital sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 11,411 shares — an estimated $167K sold.

Farringdon Capital first reported a position in ADMA in Q3 2025 and held it in 1 quarter. The position peaked at $167K in Q3 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

Farringdon Capital reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
Farringdon Capital sold 11,411 ADMA Biologics shares in Q4 2025, an estimated $167K.
Farringdon Capital first reported a position in ADMA Biologics in Q3 2025 and held it in 1 quarter.
Farringdon Capital's ADMA Biologics position peaked at $167K in Q3 2025.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on Farringdon Capital's 13F filing for Q4 2025, filed 17 Feb 2026.